NCCN Announces New Addition to Library of Guidelines: NCCN Guidelines for Lung Cancer Screening
NCCN announces the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Lung Cancer Screening, a new addition to the Complete Library of NCCN Guidelines. Lung cancer remains the leading cause of cancer-related deaths in the United States and the world; guidance on using effective screening tools for early detection can assist in the effort to decrease mortality rates.
“Currently, most lung cancer is diagnosed clinically when patients present with symptoms. Unfortunately, patients with symptoms often have advanced lung cancer,” noted Douglas E. Wood, MD, of University of Washington/Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance and chair of the NCCN Guidelines Panel for Lung Cancer Screening. “Ideally, these new guidelines combined with the continued advancement of screening tools will lead to earlier detection of the disease when treatment is more likely to be effective.”
The new NCCN Guidelines for Lung Cancer Screening primarily refer to Non-Small Cell Lung Cancer, the most common type of lung cancer, and recommend helical low-dose computed tomography (LDCT) screening for select patients at high risk for the disease.
In addition to outlining the appropriate use of LDCT screening, the NCCN Guidelines describe risk factors for lung cancer, recommend criteria for selecting high-risk individuals for screening, provide recommendations for evaluation and follow-up of nodules found during screening, detail the accuracy of LDCT screening protocols and imaging modalities, and discuss the benefits and risks of screening.
The NCCN Guidelines are developed and updated through an evidence-based process with explicit review of the scientific evidence integrated with expert judgment by multidisciplinary panels of physicians from NCCN Member Institutions. Access to the NCCN Guidelines for Lung Cancer Screening or any of the NCCN Guidelines is available free of charge at NCCN.org.
NCCN Receives $2 Million in Oncology Research Funding from Boehringer Ingelheim to Investigate Afatinib in Solid Tumors
The NCCN Oncology Research Program (ORP) has been awarded a $2 million grant from Boehringer Ingelheim Pharmaceuticals, Inc. to develop a program to scientifically evaluate and define the clinical effectiveness of Afatinib (BIBW 2992) in solid tumors, including breast, head and neck, and non-small cell lung (NSCL) cancers.
“We are excited and grateful to Boehringer Ingelheim for the opportunity to collaborate on research for Afatinib. This research grant will support innovative studies to help scientists and clinicians find new directions to advance the field of oncology. Our collaboration will provide a forum for the open exchange of information to better define the clinical application for the use of Afatinib in a variety of cancer types,” stated Diane Paul, MS, RN, vice president, ORP, NCCN.
The first phase of the program will involve the establishment of an NCCN Afatinib Request for Proposals Development Team to evaluate existing data and to discuss and define the data and type of studies necessary to further characterize the clinical effectiveness of Afatinib in selected solid tumors.
Afatinib is an oral, once-daily, targeted investigational compound currently being investigated for various tumor types, such as NSCL, breast, head and neck, and colorectal cancers and glioblastoma. It is a next generation tyrosine kinase inhibitor, which is an irreversible inhibitor of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2). Afatinib is currently in phase III clinical development for NSCL and breast cancers.
The NCCN ORP draws on the expertise of investigators at NCCN Member Institutions to facilitate all phases of clinical research. This research is made possible by collaborations with pharmaceutical and biotechnology companies in order to advance therapeutic options for patients with cancer. The NCCN ORP will utilize the grant from Boehringer Ingelheim Pharmaceuticals, Inc. to support investigator-initiated clinical and correlative studies at its NCCN Member Institutions for Afatinib. To date, this successful research model has received more than $34 million in research grants and provided 86 investigators with funding for clinical and correlative trials that have produced numerous publications in peer-reviewed journals.
NCCN Guidelines for Patients Available in Print Booklet Format
Since first launching the NCCN Guidelines for Patients a little over a year ago, NCCN has released a total of 8 patient guidelines in this new series of consumer-friendly translations of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): breast, non-small cell lung, ovarian, and prostate cancers, chronic myelogenous leukemia (CML), malignant pleural mesothelioma, melanoma, and multiple myeloma.
Although all 8 NCCN Guidelines for Patients are available online on both NCCN. org (NCCN's clinician Web site) and NCCN.com (NCCN's patient Web site), 6 are also available free of charge in print format, including breast and prostate cancers, CML, malignant pleural mesothelioma, melanoma, and multiple myeloma.
The NCCN Guidelines for Patients are regularly revised and updated based on feedback from patients and ongoing changes in the NCCN Guidelines. Any change in the NCCN Guidelines is promptly reflected in the online NCCN Guidelines for Patients to ensure they reflect the most up-to-date information. Many of the 2011 print versions of the NCCN Guidelines for Patients have recently been enhanced to contain easy-to-understand language, more pictures and graphs, and definitions of key terms to inform patients about state-of-the-art cancer treatment. The 2011 version of the NCCN Guidelines for Patients: Prostate Cancer is expected to be available in print and online by the end of the year.
To order hard copies of the six available NCCN Guidelines for Patients, please email firstname.lastname@example.org. Again, there is no charge for these booklets or for shipping. All reasonable requests will be honored.
If the inline PDF is not rendering correctly, you can download the PDF file here.